Skip to main content

Table 1 Clinical and pathological characteristics of all UTUC patients stratified by tumor location

From: Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma

  

Tumor location

Univariate analysis

All

Renal pelvis

Ureter

Chi-square or Z

p value

Patients, no. (%)

612 (100)

341 (55.7)

271 (44.3)

  

Pre-operative characteristic

 Gender, no. (%)

   

0.160

0.743

  Male

340 (55.6)

187 (54.8)

153 (56.5)

  

  Female

272 (44.4)

154 (45.2)

118 (43.5)

  

 Age, no. (%)

   

4.929

0.027*

  <70

340 (55.6)

203 (59.5)

137 (50.6)

  

   ≥ 70

272 (44.4)

138 (40.5)

134 (49.4)

  

 Age, mean ± SD

 

65.29 ± 11.11

68.07 ± 10.20

−3.173

0.002*

 Previous or concomitant bladder cancer, no. (%)

   

1.931

0.193

  Absent

545 (89.1)

309 (90.6)

236 (87.1)

  

  Present

67 (10.9)

32 (9.4)

35 (12.9)

  

 Initial complaint, no. (%)

   

24.205

< 0.001*

  Absent

84 (13.7)

26 (7.6)

58 (21.4)

  

  Present

528 (86.3)

315 (92.4)

213 (78.6)

  

 Gross hematuria, no. (%)

   

65.132

< 0.001*

  Absent

148 (24.2)

40 (11.7)

108 (39.9)

  

  Present

464 (75.8)

301 (88.3)

163 (60.1)

  

 Preoperative renal function, no. (%)

   

23.703

< 0.001*

  End-stage CKD (eGFR<15)

34 (5.6)

24 (7.0)

10 (3.7)

  

  Moderate CKD (60>eGFR≥15)

198 (32.4)

83 (24.3)

115 (42.4)

  

  Early CKD (eGFR≥60)

378 (61.8)

233 (68.3)

145 (53.5)

  

 eGFR, mean ± SD

 

69.69 ± 30.11

62.43 ± 22.32

−4.329

< 0.001*

 Side, no. (%)

   

1.115

0.329

  Left

315 (51.5)

182 (53.4)

133 (49.1)

  

  Right

297 (48.5)

159 (46.6)

138 (50.9)

  

 Hydronephrosis, no. (%)

   

134.680

< 0.001*

  Absent

273 (44.6)

223 (65.4)

50 (18.5)

  

  Present

339 (55.4)

118 (34.6)

221 (81.5)

  

 Multifocality, no. (%)

   

0.339

0.563

  Single

472 (77.1)

266 (78.0)

206 (76.0)

  

  Multiple

140 (22.9)

75 (22.0)

65 (24.0)

  

 Smoking, no. (%)

   

0.050

0.836

  No

497 (81.2)

278 (81.5)

219 (80.8)

  

  Yes

115 (18.8)

63 (18.5)

52 (19.2)

  

 Alcohol, no. (%)

   

0.697

0.452

  No

539 (88.1)

297 (87.1)

242 (89.3)

  

  Yes

73 (11.9)

44 (12.9)

29 (10.7)

  

 Diabetes, no. (%)

   

0.249

0.661

  No

511 (83.5)

287 (84.2)

224 (82.7)

  

  Yes

101 (16.5)

54 (15.8)

47 (17.3)

  

 Hypertension, no. (%)

   

4.454

0.038*

  No

363 (59.3)

215 (63.0)

148 (54.6)

  

  Yes

249 (40.7)

126 (37.0)

123 (45.4)

  

 Pre-RNU ureteroscopy, no. (%)

   

20.495

< 0.001*

  No

536 (87.6)

317 (93.0)

219 (80.8)

  

  Yes

76 (12.4)

24 (7.0)

52 (19.2)

  

Pathological outcomes

 Architecture, no. (%)

   

40.135

< 0.001*

  Papillary

479 (78.3)

299 (87.7)

180 (66.4)

  

  Sessile

133 (21.7)

42 (12.3)

91 (33.6)

  

 Tumor stage, no. (%)

   

0.094

0.796

  Ta-T1

206 (33.7)

113 (33.1)

93 (34.3)

  

  T2–4

406 (66.3)

228 (66.9)

178 (65.7)

  

 Tumor grade, no. (%)

   

31.628

< 0.001*

  G1

19 (3.1)

4 (1.2)

15 (5.5)

  

  G2

334 (54.6)

218 (63.9)

116 (42.8)

  

  G3

259 (42.3)

119 (34.9)

140 (51.7)

  

 Lymph node status, no. (%)

   

4.014

0.051

  N0 or Nx

571 (93.3)

312 (91.5)

259 (95.6)

  

  N+

41 (6.7)

29 (8.5)

12 (4.4)

  

 Non-organ-confined disease, no. (%)

   

8.257

0.004*

  No

412 (67.3)

213 (62.5)

199 (73.4)

  

  Yes

200 (32.7)

128 (37.5)

72 (26.6)

  

 Tumor size, mean ± SD

 

3.58 ± 2.15

3.27 ± 2.41

−3.342

0.001*

Histologic Subtype

 Tumor necrosis, no. (%)

   

0.038

0.901

  No

537 (87.7)

300 (88.0)

237 (87.5)

  

  Yes

75 (12.3)

41 (12.0)

34 (12.5)

  

 Squamous metaplasia, no. (%)

   

0.038

0.878

  No

566 (92.5)

316 (92.7)

250 (92.3)

  

  Yes

46 (7.5)

25 (7.3)

21 (7.7)

  

 Sarcomatoid metaplasia, no. (%)

   

0.039

0.843

  No

586 (95.8)

327 (95.9)

259 (95.6)

  

  Yes

26 (4.2)

14 (4.1)

12 (4.4)

  

 Gland-like differentiation, no. (%)

   

2.738

0.119

  No

591 (96.6)

333(97.7)

258 (95.2)

  

  Yes

21 (3.4)

8(2.3)

13 (4.8)

  

 Presence of CIS, no. (%)

   

3.987

0.071

  No

596 (97.4)

336 (98.5)

260 (95.9)

  

  Yes

16 (2.6)

5 (1.5)

11 (4.1)

  
  1. UTUC upper tract urothelial carcinoma, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, RNU radical nephroureterectomy, CIS carcinoma in situ, SD standard deviation, HR Hazard Ratio, CI confidence interval
  2. *Statistically significant